What causes ibogaine to affect the heart?

Ibogaine blocks the hERG potassium channel, which regulates the cardiac action potential's repolarization phase. When the hERG channel is inhibited, the heart muscle takes longer to reset between beats. On an electrocardiogram, this shows up as a prolonged QT interval. Severe QT prolongation can trigger torsades de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death. Ibogaine is a hERG antagonist in the low micromolar range based on cell-based assays.

OmniRx › Articles › Ibogaine and the Heart

Drug Safety · Cardiac · Federal Policy

Ibogaine and the Heart: A Clinical Decision Guide After the Federal Psychedelic Research Order

Q: How much does ibogaine prolong the QT interval?

In the most rigorous published clinical safety study, Knuijver and colleagues at a Dutch university medical center treated 14 opioid use disorder patients with ibogaine and measured an average maximum QTc prolongation of 95 milliseconds, with individual increases ranging from 29 to 146 ms. Half of the subjects reached a corrected QT (QTc) above 500 ms during the observation period. Six of 14 subjects had QTc above 450 ms lasting beyond 24 hours post-dose. No torsades de pointes were observed in this monitored setting.

Q: Is noribogaine safer than ibogaine?

Noribogaine is ibogaine's long-acting active metabolite, the active pharmaceutical ingredient in DemeRx's investigational compound DMX-1001. Noribogaine has a longer plasma half-life than ibogaine, so any cardiac effect it produces may persist longer rather than resolve more quickly. A 2026 ChemRxiv preprint authored by Vincent Wesley Couey identified noribogaine as a case where the consensus prediction rule of one widely cited hERG safety prediction model under-calls cardiac risk relative to what underlying experimental data and the model's own binary classifier suggest. Calling noribogaine 'safer' than ibogaine without prospective monitored clinical data would be premature.

Q: What questions should I ask a treatment provider about cardiac safety?

At minimum: Will I receive a baseline 12-lead electrocardiogram before dosing? What is your protocol if my baseline QTc is borderline? Do you correct potassium and magnesium to defined thresholds before dosing? Is continuous cardiac telemetry maintained throughout the dosing window, and for how many hours post-dose? What is your emergency response capability if a torsades event occurs, including defibrillator availability and IV magnesium readiness? What is your published medication exclusion list, particularly for QT-prolonging co-medications and CYP2D6 inhibitors? What follow-up monitoring is provided after discharge? Treatment programs that cannot answer all of these clearly and in writing have not earned trust on cardiac safety.

Last reviewed: May 2026 Next review: August 2026

A primary-source guide to the cardiac safety question behind the April 2026 executive order, drawing on the published clinical literature, federal labeling, and a 2026 ChemRxiv preprint on the systematic limits of current safety prediction tools for iboga-class compounds.

Executive Order · April 18, 2026 Federal landscape just changed. President Trump signed an executive order directing the HHS Secretary to allocate $50 million through ARPA-H to match state investments in psychedelic research for serious mental illness, prioritizing FDA review of psychedelic compounds and establishing a Right to Try pathway for ibogaine. The order names ibogaine twice. White House full text · Fact sheet.

Vincent Wesley Couey

Independent computational toxicology researcher. Primary author, 2026 ChemRxiv preprint on architecture-specific failure modes in hERG QSAR predictions for iboga alkaloids. Updated May 23, 2026.

ChemRxiv10.26434/15003259 OSF10.17605/OSF.IO/UWVX4

ℹ️ Medical Disclaimer: This is not medical advice. It is a source-cited reference document for patients considering ibogaine therapy, clinicians evaluating candidates, and policy readers tracking the executive order's implementation. Speak with a qualified clinician about your specific situation. Full disclosure policy.

At a glance. The April 2026 executive order does not change ibogaine's underlying cardiac risk profile. Ibogaine blocks the hERG potassium channel, prolongs the QT interval, and has been documented to cause clinically significant arrhythmia and death in unmonitored settings. The most rigorous published safety study, conducted at a Dutch university medical center, recorded an average maximum QTc prolongation of 95 milliseconds with half of subjects exceeding QTc of 500 ms. Safe administration requires baseline 12-lead ECG, electrolyte correction, continuous telemetry, and immediate emergency response capability. The federal funding now mobilizing toward this compound class makes the unanswered architecture-specific safety prediction questions urgent.

01 · Mechanism

How ibogaine affects the heart

The cardiac action potential, the electrical signal that drives each heartbeat, depends on a tightly choreographed sequence of ion channels opening and closing in the heart muscle's cell membranes. One of the most important channels in this sequence is the hERG channel (formal name: KCNH2, also called I_Kr), which conducts potassium ions out of the cell during the repolarization phase. Repolarization is the part of the heartbeat where the muscle resets so it can fire again.

When the hERG channel is blocked, repolarization slows. On a 12-lead electrocardiogram, this slowdown appears as a longer QT interval, the time from the start of the Q wave to the end of the T wave. A QT interval that is too long becomes unstable. Premature ventricular beats firing during the vulnerable late repolarization phase can trigger torsades de pointes, a polymorphic ventricular tachycardia that often self-terminates but can also degenerate into ventricular fibrillation and sudden cardiac death.

Ibogaine is a hERG channel antagonist at low micromolar concentrations in standard cell-based assays. Its long-acting active metabolite, noribogaine, is also active at the channel. Both compounds, along with a small family of structurally related natural and synthetic analogs, sit squarely in the class of pharmaceuticals that regulators flag for QT-prolongation review.

Figure 1 · Cardiac action potential and the QT interval

Where hERG blockade enters the heartbeat

A simplified cardiac action potential. The hERG channel drives repolarization (phase 3). When blocked, repolarization slows, the QT interval lengthens, and the heart becomes vulnerable to torsades de pointes.

Drug-induced QT prolongation is the standard regulatory mechanism for cardiac safety review of psychotropic compounds. The FDA and EMA evaluate it via the ICH E14 guideline (thorough QT study) and the ICH S7B nonclinical hERG assay. References: ICH E14, ICH S7B.

02 · Policy

The federal landscape just changed

On April 18, 2026, President Trump signed an executive order titled Accelerating Medical Treatments for Serious Mental Illness. The order has four operative components that matter for the ibogaine cardiac safety question:

$50 million in ARPA-H match funding directed to states that have enacted or are developing programs to advance psychedelic compounds for serious mental illness. ARPA-H, the Advanced Research Projects Agency for Health, is the high-risk-high-reward funding arm of HHS modeled after DARPA. The match-funding mechanism creates federal-state partnerships rather than direct federal grants.
FDA prioritized review of psychedelic compounds, with companion direction to the DEA and other federal agencies to reduce administrative friction around Schedule I research.
A Right to Try access pathway for eligible patients to receive investigational psychedelic compounds, with ibogaine named explicitly in the order text. Right to Try, established under the 2018 federal statute of the same name, allows patients with life-threatening conditions to access investigational drugs that have completed Phase 1 trials.
An interagency working group coordinating FDA, NIH, VA, DEA, and HHS implementation.

HHS Secretary Robert F. Kennedy Jr., in the official statement accompanying the order, named ibogaine specifically alongside other compounds. The signing ceremony featured veteran advocates including W. Bryan Hubbard (Americans for Ibogaine), the Luttrell brothers, and Joe Rogan, signaling that ibogaine for veterans is a primary political driver of the order.

The cardiac question this creates. The Right to Try statute requires that an investigational drug have completed Phase 1 safety trials. Ibogaine's status here is contested. The FDA has historically resisted ibogaine research partly because of unresolved cardiac safety questions. Independent legal analysts including Frier Levitt and the Petrie-Flom Center at Harvard Law have flagged this gap as the central legal and clinical risk of the order's expansive ibogaine pathway.

Figure 2 · Federal funding pipeline post-EO

Where the $50M flows and what it has to answer

ARPA-H match funding routes through state partners to research programs, while a parallel Right to Try track opens patient access. The unresolved cardiac safety prediction question sits at the intersection.

03 · Clinical Data

What the clinical literature actually shows

The published clinical and forensic evidence on ibogaine's cardiac effects rests on three foundations: case series from unregulated treatment settings, prospective monitored dosing studies, and pharmacokinetic-pharmacodynamic modeling. Each tells a different part of the same story.

The Alper forensic case series

In 2012, Kenneth Alper, Milena Stajic, and James Gill published a systematic review in the Journal of Forensic Sciences of all available autopsy, toxicology, and investigative reports for ibogaine-associated fatalities outside West Central Africa between 1990 and 2008. They identified 19 fatalities, comprising 15 men and 4 women aged 24 to 54, all dying within 1.5 to 76 hours of ibogaine ingestion. Subsequent reports have brought the documented total to approximately 33. The deaths occurred predominantly in unregulated settings without cardiac monitoring, electrolyte management, or trained emergency response. Pre-existing cardiovascular disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), and co-administered drugs that prolong QT or interact with ibogaine's metabolism were identified as common factors.

The Alper series is the most cited primary source on ibogaine mortality. It is also the source most frequently misrepresented in both directions: opponents cite the absolute number as proof of a uniquely lethal drug, while advocates point out that monitored clinical settings have a very different risk profile. Both readings are partial.

The Knuijver monitored dosing studies

The most rigorous prospective safety data come from Knuijver and colleagues at a Dutch university medical center, who treated 14 patients with opioid use disorder under continuous cardiac monitoring. The 2022 publication in Addiction reported:

Average maximum QTc (Fridericia correction) prolongation of 95 milliseconds, with individual increases ranging from 29 to 146 ms.
50% of subjects reached a QTc above 500 ms during the observation period. A QTc above 500 ms is the threshold above which torsades risk is considered clinically significant.
6 of 14 subjects had QTc above 450 ms lasting beyond 24 hours after ingestion, indicating that the cardiac effect outlasts the acute dosing window.
Severe transient ataxia (inability to walk without support) in all 14 patients.
No torsades de pointes events, in a setting with continuous telemetry, electrolyte management, and immediate response capability.

A follow-up 2024 pharmacokinetic-pharmacodynamic analysis from the same group characterized the exposure-response relationship between ibogaine, its metabolite noribogaine, and the magnitude of QTc change. Noribogaine, with its longer plasma half-life, accounts for the persistent QTc effect beyond 24 hours.

What the Knuijver data tells us, and does not. In a monitored setting with electrolyte correction and continuous telemetry, ibogaine produces clinically significant QTc prolongation in essentially every patient but did not produce torsades in 14 subjects. This is consistent with the broader regulatory observation that hERG blockade is necessary but not sufficient for arrhythmia: the surrounding clinical environment, including potassium and magnesium status, concomitant QT-prolonging drugs, baseline cardiac substrate, and timeliness of response to ventricular ectopy, determines whether QTc prolongation becomes torsades. A 14-patient study cannot rule out lower-frequency but catastrophic events.

04 · Prediction Tools

Why current safety-prediction tools miss part of the picture

Pharmaceutical regulators do not rely on monitored clinical trials alone to assess cardiac risk. Long before a compound reaches a Phase 1 study, computational structure-activity prediction tools (QSAR models, for quantitative structure-activity relationship) screen molecules against hERG blockade. These models are trained on tens of thousands of compounds with measured hERG IC₅₀ values. Regulators, pharmaceutical companies, and academic groups all use them. They are the first line of cardiac safety triage.

The unresolved question is how well these models perform on chemical scaffolds that are underrepresented in their training data. Iboga alkaloids, with their characteristic ibogamine indole-isoquinuclidine fused ring system, are an example of a scaffold class for which prediction-tool performance has not been systematically evaluated until recently.

In a 2026 ChemRxiv preprint I authored (DOI 10.26434/chemrxiv.15003259/v1, with full pre-registration archived on the Open Science Framework at DOI 10.17605/OSF.IO/UWVX4), I tested three architecturally distinct hERG QSAR models against the iboga alkaloid family. The compounds tested included naturally occurring potent blockers (ibogaine, voacangine, noribogaine), and designed safer-scaffold analogs (18-methoxycoronaridine and tabernanthalog) developed as candidate next-generation psychedelic therapeutics with reduced cardiac liability.

The central finding is what I term an architecture-specific asymmetric failure pattern. The same compound class produces opposite-direction prediction errors depending on which model architecture is asked:

Architecture-specific failure pattern on iboga alkaloids

Each model architecture systematically misclassifies a different subset. Graph neural networks and SVMs over-call cardiac risk on designed safer-scaffold analogs. Gradient-boosted ECFP4 models under-call risk on natural potent blockers.

The clinical-relevance translation: a regulator or clinical investigator using a graph neural network model alone might conclude that 18-methoxycoronaridine and tabernanthalog, two next-generation candidates explicitly designed to retain ibogaine's therapeutic activity while reducing hERG blockade, look too cardiotoxic to advance. The same regulator using a gradient-boosted ECFP4 model alone might conclude that noribogaine, the active pharmaceutical ingredient in DemeRx's DMX-1001 investigational compound, is below the threshold for routine cardiac screening. Neither conclusion is correct on the underlying data. The same compound family breaks the prediction tools in opposite directions depending on which tool is consulted.

Methodology and audit trail. All compound predictions were generated under pre-registered statistical priors archived on the Open Science Framework before the canonical-SMILES reruns were executed. Of eight pre-registered priors, eight landed within the registered probability ranges, indicating that the failure pattern was not the result of post-hoc model selection. Full audit trail and per-compound prediction JSONs are public at OSF project tnpqv. The methodology lineage traces to a Substrate Geometry physics research program with the same pre-commit and falsification discipline.

The next-generation compounds: a closer look

The five compounds in the analysis above are the substrate of the post-EO research conversation. Each occupies a distinct position in the iboga alkaloid family, with different therapeutic targets and different cardiac safety profiles.

Ibogaine Natural alkaloid · Tabernanthe iboga The parent compound. Used in unregulated and offshore clinical settings for opioid use disorder. Potent hERG blocker. Under-called by ECFP4 consensus

Noribogaine 12-OH-ibogamine · DMX-1001 API Long-acting active metabolite of ibogaine. Active pharmaceutical ingredient in DemeRx's investigational compound. Under-called by ECFP4 consensus

Voacangine Natural alkaloid · Voacanga A biosynthetic precursor to ibogaine. Independently active at hERG. Less studied clinically. Under-called by ECFP4 consensus

18-Methoxycoronaridine 18-MC · designed analog Synthetic ibogaine analog explicitly designed for reduced cardiac liability. Has advanced through early human trials. Over-called by GNN + SVM

Tabernanthalog TBG · designed analog A non-hallucinogenic ibogaine-inspired scaffold from Olson's UC Davis program. Preclinical-stage candidate. Over-called by GNN + SVM

05 · Risk Modifiers

Risk modifiers: what raises the cardiac stakes

Ibogaine's cardiac risk is not uniform across patients. A patient with a baseline QTc of 410 ms, normal electrolytes, no QT-prolonging co-medications, and no congenital long-QT history is at a fundamentally different starting point than a patient with a baseline QTc of 460 ms on methadone with low magnesium. The risk modifiers below are drawn from FDA QT guidance, the published torsadogenic risk literature (CredibleMeds and the AZCERT consortium), and the Knuijver studies.

Modifier	Risk weight	Why it matters
Baseline QTc > 450 ms (male) or > 460 ms (female)	High	Starting point determines how much headroom remains before crossing the 500 ms torsades-risk threshold under ibogaine's 95 ms average prolongation.
Hypokalemia (K+ < 4.0 mEq/L)	High	Low potassium independently prolongs QT and amplifies hERG blockers. Correction to K+ ≥ 4.0 mEq/L is standard pre-dose practice in monitored protocols.
Hypomagnesemia (Mg++ < 2.0 mg/dL)	High	Magnesium stabilizes cardiac repolarization. IV magnesium is also the first-line torsades treatment, so depletion is doubly dangerous.
Methadone or other strong QT-prolonging opioids	High	Methadone itself is a hERG blocker and a recognized torsadogen. The combination with ibogaine is particularly concerning in OUD treatment populations where methadone maintenance is common.
Concurrent QT-prolonging drugs (certain macrolides, fluoroquinolones, antifungals, antipsychotics, antidepressants)	High	Additive QT effects. The CredibleMeds list at crediblemeds.org stratifies drugs by torsadogenic risk and is the standard reference for screening.
CYP2D6 inhibitors or CYP2D6 poor metabolizer status	Moderate	Ibogaine is metabolized to noribogaine via CYP2D6. Poor metabolizers and patients on strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) have elevated ibogaine exposure and altered metabolite ratios.
Congenital long-QT syndrome or family history of sudden cardiac death	High	Latent channelopathies dramatically lower the threshold for drug-induced torsades. Most monitored protocols exclude patients with cLQTS or first-degree-relative sudden death history.
Structural heart disease, cardiomyopathy, recent MI	High	A vulnerable myocardial substrate makes any drug-induced electrical perturbation more dangerous.
Bradycardia or AV nodal disease	Moderate	Ibogaine itself causes bradycardia. Combined with pre-existing conduction system disease, the effect can compound.
Female sex	Modifier	Women have on average longer baseline QTc and higher torsades susceptibility from any given hERG blocker, established in the broader drug-induced QT literature.
Age > 65	Modifier	Age-related electrolyte handling, polypharmacy burden, and structural heart prevalence raise risk.

06 · Clinical Decisions

What to ask a treatment provider

The single highest-value action a patient or family member can take before any ibogaine session is to obtain written answers to a defined set of cardiac safety questions. Programs that cannot answer these clearly and in writing have not earned trust on cardiac safety. The list below is structured around the four domains where the published mortality cases concentrate: screening, dosing-window monitoring, emergency response, and post-discharge follow-up.

Figure 3 · Pre-treatment cardiac safety decision flow

The four-domain decision frame

A patient or referring clinician evaluating a treatment program should obtain explicit answers in each of the four domains below. Failure to answer is itself an answer.

Screening questions

Will I receive a baseline 12-lead electrocardiogram before dosing? Who reads it, and what QTc threshold disqualifies me?
What electrolyte panel do you run pre-dose? What are your minimum thresholds for potassium and magnesium? Are corrections completed before dosing or alongside it?
What is your written medication exclusion list? Does it cover QT-prolonging co-medications (the CredibleMeds list at minimum), CYP2D6 inhibitors, and methadone?
Do you screen for congenital long-QT syndrome and family history of sudden cardiac death?
Do you require a recent (within 6 months) echocardiogram or any imaging for structural heart disease?

Dosing-window monitoring

Is continuous cardiac telemetry maintained throughout the dosing window? For how many hours post-dose?
What is the patient-to-clinician ratio during the acute dosing window?
How often is QTc re-checked during monitoring? What change triggers escalation?
How is the dosing room equipped: oxygen, suction, IV access, defibrillator within reach?

Emergency response

Is the medical team ACLS-certified? Is a physician on-site or on immediate call?
Is intravenous magnesium drawn up and accessible before dosing begins, as first-line treatment if torsades occurs?
What is the time and route to a full-service emergency department if transfer becomes necessary?
Have torsades events occurred in your program? How were they managed? What were the outcomes?

Post-discharge follow-up

Is a post-discharge ECG required before I leave the facility?
Given that the Knuijver data shows QTc above 450 ms persisting beyond 24 hours in 6 of 14 patients, what activity, medication, and follow-up restrictions do you place on the 24- to 72-hour post-dose window?
What follow-up contact does your program provide at 24 hours, 7 days, 14 days, and 30 days?

The single most useful disqualifier. If a program markets ibogaine as fundamentally safe, dismisses cardiac monitoring as overcautious medicalization, or attributes documented fatalities solely to other factors without engaging with the hERG mechanism, treat that as a hard signal. The Knuijver data establishes that QTc prolongation happens in essentially every patient at therapeutic doses. A program that does not concede this is either uninformed or actively misrepresenting the safety profile.

07 · Research Agenda

Where the science needs to go, post-EO

The executive order's $50 million ARPA-H match-funding pot and the broader federal pivot create a near-term funding window for cardiac safety research on iboga-class compounds. The questions that the published literature and the QSAR analysis described above leave unresolved, and that this funding window is positioned to answer, include:

Prospective architecture-stratified hERG and QTc validation studies. Run the standard regulatory hERG assay, the ICH E14 thorough QT study, and a clinical telemetry cohort against the five compounds in the iboga family with sufficient sample size to detect the asymmetric failure pattern documented in the Paper I preprint. The point is not to re-litigate ibogaine's known liability but to determine which prediction tool architecture should be relied upon for the next-generation compounds (18-MC, tabernanthalog, noribogaine) that the EO's Right to Try pathway will channel patients toward.
Applicability domain (AD) characterization for hERG QSAR on natural-product scaffolds. If iboga alkaloids fall outside the training-data domain of widely deployed models, that fact should be characterized formally and surfaced to regulators, sponsors, and clinical investigators rather than left as an implicit caveat.
Binding-versus-blockade dissociation studies. The Paper I central mechanistic finding is that some compounds bind to the hERG channel but produce less functional blockade than binding affinity alone would predict, and vice versa. This dissociation is the root cause of the asymmetric failure pattern. Programmatic study of it across psychedelic-class scaffolds is the kind of mechanism-anchored work an ARPA-H program could meaningfully fund.
Real-world QTc registries tied to state Right to Try pathways. If patients are accessing ibogaine through state-administered Right to Try, a federally coordinated cardiac registry capturing baseline ECG, electrolytes, dose, peak QTc, time-to-recovery, and adverse events would build the prospective data that the field currently lacks.
Pharmacogenomic CYP2D6 stratification. Poor and intermediate CYP2D6 metabolizers experience higher ibogaine exposure and a different ibogaine-to-noribogaine ratio. Pre-dose genotyping is feasible and cheap. Its incorporation into clinical protocols is an open question that the funding window can resolve.

Each of these items maps cleanly to an ARPA-H research priority area, and each has direct implications for the cardiac safety profile a Right to Try patient is exposed to. The Paper I preprint is one input to a broader research agenda that the federal pivot has now made urgent. Independent researchers, sponsors, and academic investigators with active programs in any of these areas are welcome to reach me using the contact information below.

08 · FAQ

Frequently asked questions

Is ibogaine safe to use after the April 2026 executive order?

The executive order does not change ibogaine's underlying cardiac risk profile. Ibogaine remains a Schedule I substance under U.S. federal law, and its mechanism for causing QT prolongation (hERG potassium channel blockade) is unchanged. What the order does is direct $50 million through ARPA-H to match state-funded research, prioritize FDA review of psychedelic compounds, and open a Right to Try pathway for investigational ibogaine compounds. Safety still depends on baseline cardiac screening, electrolyte management, and continuous telemetry during dosing in qualified treatment settings.

Is ibogaine now legal in the United States?

No. Ibogaine remains a Schedule I controlled substance under the Controlled Substances Act. The executive order does not reschedule it. What the order does is open access pathways for eligible patients through the federal Right to Try statute, and accelerate FDA review of investigational ibogaine compounds. State-level frameworks (Texas, Kentucky and others have advanced ibogaine-specific legislation in recent years) operate alongside the federal framework and vary widely.

How much does ibogaine prolong the QT interval?

In the most rigorous published clinical safety study (Knuijver et al, Addiction 2022), the average maximum QTc prolongation across 14 monitored opioid use disorder patients was 95 milliseconds, with individual increases ranging from 29 to 146 ms. Half of subjects reached a QTc above 500 ms during observation. Six of 14 had QTc above 450 ms lasting beyond 24 hours post-dose. No torsades de pointes were observed in this monitored setting.

Have people died from ibogaine?

Yes. A peer-reviewed forensic case series by Alper, Stajic and Gill in the Journal of Forensic Sciences (2012) documented 19 fatalities outside West Central Africa between 1990 and 2008, occurring within 1.5 to 76 hours of ibogaine ingestion. Subsequent case reports have brought the documented total to approximately 33. The majority occurred in unregulated settings without cardiac telemetry, electrolyte correction, or emergency response capability. Cardiac causes including QT prolongation and arrhythmia are implicated in a substantial proportion of the fatalities, though contributing factors (pre-existing disease, electrolyte status, concomitant drugs) varied across cases.

Is noribogaine safer than ibogaine?

Noribogaine is ibogaine's long-acting active metabolite, and the active pharmaceutical ingredient in DemeRx's investigational compound DMX-1001. It has a substantially longer plasma half-life than ibogaine. Any cardiac effect noribogaine produces persists longer rather than resolves more quickly. A 2026 ChemRxiv preprint identified noribogaine as a case where a widely cited hERG safety prediction model's consensus rule under-calls cardiac risk relative to what the underlying experimental data and the model's own binary classifier indicate. Calling noribogaine "safer" than ibogaine without prospective monitored clinical data would be premature.

What is the executive order's $50 million ARPA-H funding actually for?

The order directs the HHS Secretary to allocate $50 million through the Advanced Research Projects Agency for Health to match state-government investments in psychedelic research programs targeting populations with serious mental illness. The funding mechanism is a federal-state partnership: ARPA-H provides matching dollars, technical assistance, and data-sharing infrastructure, while states drive program design. The order separately prioritizes FDA review of psychedelic compounds and establishes a Right to Try access pathway for eligible patients to receive investigational ibogaine compounds.

What questions should I ask a treatment provider about cardiac safety?

At minimum: Will I receive a baseline 12-lead ECG before dosing? What is your protocol if my baseline QTc is borderline? Do you correct potassium and magnesium to defined thresholds before dosing? Is continuous cardiac telemetry maintained throughout the dosing window, and for how many hours post-dose? What is your emergency response capability if a torsades event occurs (defibrillator availability, IV magnesium readiness, ACLS-trained team)? What is your published medication exclusion list? What follow-up monitoring is provided after discharge? Treatment programs that cannot answer all of these clearly and in writing have not earned trust on cardiac safety. The full 16-question framework appears in Section 6 above.

Why do different prediction models disagree about ibogaine and its analogs?

A 2026 ChemRxiv preprint documented an architecture-specific asymmetric failure pattern: graph neural network and SVM-based hERG QSAR models over-call cardiac risk on designed safer-scaffold ibogaine analogs (18-methoxycoronaridine and tabernanthalog), while a gradient-boosted ECFP4 model's consensus rule under-calls risk on natural potent blockers (ibogaine, voacangine, noribogaine). The root cause is that the iboga alkaloid scaffold sits at the edge of the training data domain for these models. Different model architectures handle that edge differently, producing opposite-direction errors on the same compound family.

09 · Sources

Source ledger

Every clinical and policy claim in this guide rests on a primary source. Vincent Couey's ChemRxiv preprint and OSF pre-registration are cited only for claims about the architecture-specific hERG QSAR failure pattern documented in that paper. All other claims rest on the regulatory, peer-reviewed, and government sources listed below.

EO Executive Order: Accelerating Medical Treatments for Serious Mental Illness. Signed April 18, 2026. Full text and accompanying fact sheet. whitehouse.gov ›

Preprint Couey, V. W. (2026). Architecture-Specific Failure Modes in hERG QSAR Predictions for Iboga Alkaloids. ChemRxiv. DOI 10.26434/chemrxiv.15003259/v1. chemrxiv.org ›

Pre-registration Couey, V. W. (2026). Pre-registration and audit trail for Paper I. Open Science Framework. DOI 10.17605/OSF.IO/UWVX4. osf.io ›

Peer-reviewed Alper, K. R., Stajic, M., & Gill, J. R. (2012). Fatalities Temporally Associated with the Ingestion of Ibogaine. Journal of Forensic Sciences, 57(2), 398-412. DOI 10.1111/j.1556-4029.2011.02008.x. PubMed ›

Peer-reviewed Knuijver, T. et al. (2022). Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction, 117(1), 118-128. DOI 10.1111/add.15448. PubMed ›

Peer-reviewed Knuijver, T. et al. (2024). The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients. Journal of Psychopharmacology. DOI 10.1177/02698811241237873. PubMed ›

Regulatory FDA Drug Safety Communication and the ICH E14 / S7B guidelines on QT/QTc evaluation and nonclinical hERG assays. Standard regulatory framework for drug-induced QT prolongation review. fda.gov ›

Regulatory reference CredibleMeds / AZCERT QT drug lists. Standard clinical reference for torsadogenic risk stratification of co-medications. crediblemeds.org ›

Policy analysis Petrie-Flom Center (Harvard Law). Q&A on the Executive Order with I. Glenn Cohen and Mason Marks, April 2026. petrieflom.law.harvard.edu ›

Policy analysis Frier Levitt. The Psychedelics Executive Order: Priority Review Vouchers, Ibogaine's Cardiac Shadow, and the Road Ahead. April 2026. frierlevitt.com ›

Corrections policy. If you identify a factual error, an outdated citation, or a primary-source disagreement with anything stated here, contact vinnycouey@gmail.com. Substantive corrections are logged in the corresponding OSF audit-trail entry with an explanatory note appended to this article's revision history.

Vincent Wesley Couey

Independent computational toxicology researcher. Primary author of the 2026 ChemRxiv preprint on architecture-specific failure modes in hERG QSAR predictions for iboga alkaloids, with pre-registered audit trail on the Open Science Framework. Builder of the OmniRx consumer pharmacy intelligence platform. Methodology lineage traces to a Substrate Geometry physics research program with pre-commit and falsification discipline. Contact: vinnycouey@gmail.com.

ChemRxiv Paper I OSF pre-registration DeepSynthesis chemistry hub About page